Table 2.
Numbers of lymphocyte subsets in spleen at end of the treatment.
| No. of cells (×106) (mean ± SD) | Sham | Vehicle | MMF | MSC2360844 6.6 mg/kg | MSC2360844 22 mg/kg | MSC2360844 66 mg/kg | MSC2360844 66 mg/kg (L) |
|---|---|---|---|---|---|---|---|
| Total splenocytes | 33.34* (±12.53) | 51.94 (±19.70) | 46.50 (±25.17) | 51.90 (±25.17) | 46.64 (±21.37) | 38.41 (±11.39) | 37.79 (±15.17) |
| B220+CD19+ (total B cells) | 13.28* (±7.16) | 24.92 (±9.89) | 20.65 (±6.54) | 24.52 (±13.69) | 21.75 (±11.10) | 18.07 (±5.91) | 16.08 (±8.59) |
| CD138+ (plasma cells) | 0.22* (±0.23) | 0.84 (±0.32) | 0.43 (±0.28) | 0.67 (±0.50) | 0.52 (±0.54) | 0.23* (±0.13) | 0.27* (±0.28) |
| GL-7+IgG− (GC B cells) | 0.18 (±0.20) | 0.46 (±0.22) | 0.23 (±0.16) | 0.49 (±0.18) | 0.42 (±0.24) | 0.18 (±0.11) | 0.20 (±0.15) |
| IgG+ (class-switched B cells) | 0.13 (±0.07) | 0.24 (±0.18) | 0.17 (±0.05) | 0.18 (±0.13) | 0.19 (±0.08) | 0.12* (±0.03) | 0.13 (±0.07) |
| CD3+ (total T-cells) | 16.26 (±3.83) | 15.90 (±4.75) | 21.05 (±6.83) | 19.44 (±5.39) | 21.22 (±5.95) | 17.90 (±5.57) | 16.29 (±4.69) |
| CD4+ CD44owlow CD62Lighhigh (naive CD4+ T-cells) | 5.39 (±1.32) | 3.50 (±1.53) | 6.77* (±2.57) | 6.03 (±1.64) | 7.08* (±1.35) | 6.59* (±2.43) | 5.61 (±1.62) |
| CD4+ CD44ighhigh CD62Lowlow (activated CD4+ T-cells) | 3.38* (±1.82) | 7.23 (±3.00) | 5.24 (±2.05) | 6.10 (±4.51) | 5.30 (±3.19) | 3.03* (±1.31) | 3.44 (±2.23) |
| CD8+ CD44owlow CD62Lighhigh (naive CD8+ cells) | 4.13* (±1.12) | 2.07 (±0.80) | 5.06* (±1.76) | 3.78 (±0.95) | 4.89* (±1.89) | 5.15 (±1.74) | 4.19* (±1.37) |
| CD8+ CD44ighhigh CD62Lowlow (activated CD8+ T-cells) | 0.18* (±0.08) | 0.46 (±0.25) | 0.23 (±0.09) | 0.33 (±0.21) | 0.34 (±0.28) | 0.21 (±0.09) | 0.26 (±0.22) |
Statistical analysis; one-way ANOVA followed by Dunnett’s test versus vehicle group. *p < 0.05.